Mechanisms of Optic Nerve Stroke Neuroprotection

视神经中风的神经保护机制

基本信息

  • 批准号:
    8762089
  • 负责人:
  • 金额:
    $ 38.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-08-01 至 2019-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Nonarteritic anterior ischemic optic neuropathy (NAION) is an optic nerve (ON) infarct, and the most common cause of sudden optic nerve (ON) related vision loss, NAION affects ~15,000 individuals/year and has no effective treatments. Little is known about the mechanisms in NAION pathophysiology. Our lab developed the first rodent and primate NAION models that have been validated for nearly every finding found in NAION, and us to critically dissect NAIONs likely processes. We have determined that early and late inflammatory changes play a key role in NAION model development and damage. Soon after NAION model induction, ON head edema and a compartment syndrome occur along with soluble inflammatory cytokine expression and progressive ischemia. Later (>3d) changes include significant cellular inflammatory infiltration, with increased M1 (degenerative macrophage response) and decreased M2 (regenerative macrophage response) activities, and progressive axon- and oligodendrocyte damage. These responses ultimately result in retinal ganglion cell (RGC) and oligodendrocyte death. We identified prostaglandin J2 (PGJ2) as the first agent that can potentially treat early stage disease. In aim 1, we will separately evaluate PGJ2's neuroprotective mechanisms, confirming their individual identities and their maximal effects. We will then determine whether these mechanisms act synergistically, to maximize neuroprotection. In aim 2, we will determine whether selectively immunomodulating the neuroprotective M2 macrophage inflammatory response will reduce RGC and myelin dysfunction and cellular death, and improve post-infarct recovery. Results of these interventions will be evaluated using a variety of techniques, to quantify effects at the gene expression level, histochemically and functionally. This combination early and later approaches is designed to maximize development of clinically effective treatments for NAION and related diseases, and greatly improve post- NAION recovery.
描述(由申请人提供):非动脉炎性前部缺血性视神经病变(NAION)是一种视神经(ON)梗死,是突发性视神经(ON)相关视力丧失的最常见原因,NAION每年影响约15,000例患者,目前尚无有效治疗方法。关于NAION的病理生理学机制知之甚少。我们的实验室开发了第一个啮齿动物和灵长类动物NAION模型,这些模型已经被验证用于NAION中发现的几乎每一个发现,我们批判性地剖析了NAION可能的过程。我们已经确定早期和晚期炎症变化在NAION模型的发展和损伤中起关键作用。在NAION模型诱导后不久,ON头部水肿和室间隔综合征伴随可溶性炎性细胞因子表达和进行性缺血发生沿着。后期(>3d)变化包括显著的细胞炎症浸润,M1(退行性巨噬细胞反应)活性增加,M2(再生巨噬细胞反应)活性降低,以及进行性轴突和少突胶质细胞损伤。这些反应最终导致视网膜神经节细胞(RGC)和少突胶质细胞死亡。我们将前列腺素J2(PGJ2)确定为第一种可能治疗早期疾病的药物。在目标1中,我们将单独评估PGJ 2的神经保护机制,确认它们的个体身份和最大效果。然后,我们将确定这些机制是否协同作用,以最大限度地保护神经。在目标2中,我们将确定选择性免疫调节神经保护性M2巨噬细胞炎症反应是否会减少RGC和髓鞘功能障碍和细胞死亡,并改善梗死后恢复。这些干预措施的结果将使用各种技术进行评估,以量化基因表达水平,组织化学和功能的影响。这种早期和晚期方法的组合旨在最大限度地开发NAION和相关疾病的临床有效治疗方法,并大大改善NAION后的恢复。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STEVEN L BERNSTEIN其他文献

STEVEN L BERNSTEIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STEVEN L BERNSTEIN', 18)}}的其他基金

The role of optic nerve lamina region stem cells in age-related optic nerve disease
视神经板区域干细胞在年龄相关性视神经疾病中的作用
  • 批准号:
    10443202
  • 财政年份:
    2022
  • 资助金额:
    $ 38.38万
  • 项目类别:
The role of optic nerve lamina region stem cells in age-related optic nerve disease
视神经板区域干细胞在年龄相关性视神经疾病中的作用
  • 批准号:
    10707014
  • 财政年份:
    2022
  • 资助金额:
    $ 38.38万
  • 项目类别:
Preclinical Analysis of Ischemic Optic Nerve Treatment
缺血性视神经治疗的临床前分析
  • 批准号:
    9367979
  • 财政年份:
    2017
  • 资助金额:
    $ 38.38万
  • 项目类别:
Preclinical analysis of ischemic optic nerve treatment
缺血性视神经治疗的临床前分析
  • 批准号:
    8531941
  • 财政年份:
    2009
  • 资助金额:
    $ 38.38万
  • 项目类别:
Preclinical analysis of ischemic optic nerve treatment
缺血性视神经治疗的临床前分析
  • 批准号:
    8138465
  • 财政年份:
    2009
  • 资助金额:
    $ 38.38万
  • 项目类别:
Preclinical analysis of ischemic optic nerve treatment
缺血性视神经治疗的临床前分析
  • 批准号:
    7908779
  • 财政年份:
    2009
  • 资助金额:
    $ 38.38万
  • 项目类别:
Preclinical analysis of ischemic optic nerve treatment
缺血性视神经治疗的临床前分析
  • 批准号:
    8328685
  • 财政年份:
    2009
  • 资助金额:
    $ 38.38万
  • 项目类别:
Preclinical analysis of ischemic optic nerve treatment
缺血性视神经治疗的临床前分析
  • 批准号:
    7636201
  • 财政年份:
    2009
  • 资助金额:
    $ 38.38万
  • 项目类别:
Mechanisms of Optic Nerve Stroke Neuroprotection
视神经中风的神经保护机制
  • 批准号:
    8901174
  • 财政年份:
    2004
  • 资助金额:
    $ 38.38万
  • 项目类别:
A functional approach to treating optic nerve stroke
治疗视神经中风的功能性方法
  • 批准号:
    7077651
  • 财政年份:
    2004
  • 资助金额:
    $ 38.38万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.38万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 38.38万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.38万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.38万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.38万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.38万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.38万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 38.38万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 38.38万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 38.38万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了